Dalekos GN - Search Results

1

An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.

Kim HY, Lampertico P, Nam JY, Lee HC, Kim SU, Sinn DH, Seo YS, Lee HA, Park SY, Lim YS, Jang ES, Yoon EL, Kim HS, Kim SE, Ahn SB, Shim JJ, Jeong SW, Jung YJ, Sohn JH, Cho YK, Jun DW, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen HLA, Jang MJ, Lee YB, Kim YJ, Yoon JH, Papatheodoridis GV, Lee JH. Kim HY, et al. Among authors: dalekos gn. J Hepatol. 2022 Feb;76(2):311-318. doi: 10.1016/j.jhep.2021.09.025. Epub 2021 Oct 2. J Hepatol. 2022. PMID: 34606915

2

A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis.

Dalekos GN, Christodoulou D, Kistis KG, Zervou EK, Hatzis J, Tsianos EV. Dalekos GN, et al. Eur J Gastroenterol Hepatol. 1998 Nov;10(11):933-9. doi: 10.1097/00042737-199811000-00006. Eur J Gastroenterol Hepatol. 1998. PMID: 9872615

3

Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment.

Dalekos GN, Wedemeyer H, Obermayer-Straub P, Kayser A, Barut A, Frank H, Manns MP. Dalekos GN, et al. J Hepatol. 1999 Mar;30(3):366-75. doi: 10.1016/s0168-8278(99)80092-0. J Hepatol. 1999. PMID: 10190716

4

Alterations of leptin during IFN-alpha therapy in patients with chronic viral hepatitis.

Zografos TA, Rigopoulou EI, Liaskos C, Togousidis E, Zachou K, Gatselis N, Germenis A, Dalekos GN. Zografos TA, et al. Among authors: dalekos gn. J Hepatol. 2006 May;44(5):848-55. doi: 10.1016/j.jhep.2006.01.025. Epub 2006 Feb 17. J Hepatol. 2006. PMID: 16530290 Clinical Trial.

5

Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients.

Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Zachou K, et al. Among authors: dalekos gn. J Hepatol. 2011 Sep;55(3):636-646. doi: 10.1016/j.jhep.2010.12.032. Epub 2011 Jan 14. J Hepatol. 2011. PMID: 21238519 Clinical Trial.

6

Autoimmune hepatitis in patients with chronic HBV and HCV infections: patterns of clinical characteristics, disease progression and outcome.

Rigopoulou EI, Zachou K, Gatselis N, Koukoulis GK, Dalekos GN. Rigopoulou EI, et al. Among authors: dalekos gn. Ann Hepatol. 2013 Jan-2014 Feb;13(1):127-35. Ann Hepatol. 2013. PMID: 24378276 Free article.

7

Hepatocellular carcinoma risk in HBeAg-negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort.

Papatheodoridis GV, Manolakopoulos S, Touloumi G, Nikolopoulou G, Raptopoulou-Gigi M, Gogos C, Vafiadis-Zouboulis I, Karamanolis D, Chouta A, Ilias A, Drakoulis C, Mimidis K, Ketikoglou I, Manesis E, Mela M, Hatzis G, Dalekos GN; HepNet.Greece Study Group. Papatheodoridis GV, et al. Among authors: dalekos gn. J Viral Hepat. 2015 Feb;22(2):120-7. doi: 10.1111/jvh.12283. Epub 2014 Jul 15. J Viral Hepat. 2015. PMID: 25040685

8

Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis.

Zachou K, Gampeta S, Gatselis NK, Oikonomou K, Goulis J, Manoussakis MN, Renaudineau Y, Bogdanos DP, Dalekos GN. Zachou K, et al. Among authors: dalekos gn. Liver Int. 2015 Feb;35(2):660-72. doi: 10.1111/liv.12658. Epub 2014 Aug 27. Liver Int. 2015. PMID: 25113420

9

Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.

Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Papatheodoridis GV, et al. Among authors: dalekos gn. J Hepatol. 2015 Feb;62(2):363-70. doi: 10.1016/j.jhep.2014.08.045. Epub 2014 Sep 6. J Hepatol. 2015. PMID: 25195548

10

On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients.

Goulis I, Karatapanis S, Akriviadis E, Deutsch M, Dalekos GN, Raptopoulou-Gigi M, Mimidis K, Germanidis G, Drakoulis C, Triantos C, Zintzaras E, Bakalos G, Papatheodoridis G. Goulis I, et al. Among authors: dalekos gn. Liver Int. 2015 May;35(5):1540-8. doi: 10.1111/liv.12725. Epub 2014 Nov 20. Liver Int. 2015. PMID: 25368957

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

310 results

Search Page